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S U M M A R Y
Objectives: This study investigated the prevalence of diverse Ambler class b-lactamase-encoding genes
in 40 carbapenem-insensitive Acinetobacter baumannii isolates collected from two hospitals in Egypt
during the period January–March 2012.
Methods: The resistance levels to different groups of antimicrobial agents were determined. PCR was
used to detect the different Ambler class b-lactamases encoding the following genes: blaTEM, blaSHV,
blaCTX-M, blaVEB, blaPER, blaGES, blaVIM, blaIMP, blaSIM, blaSPM, blaGIM, blaNDM, blaADC, blaOXA-23, blaOXA-24,
blaOXA-51, and blaOXA-58. ISAba1 and int1 were detected by PCR.
Results: The isolates were 100% resistant to amoxicillin–clavulanate, aztreonam, cefepime, cefotaxime,
and ceftazidime. Of the isolates, 5% were resistant to colistin, 45% to amikacin, 70% to imipenem, and 85%
to ciproﬂoxacin. The blaADC- and blaOXA-51-like genes were detected in the entire collection. The
prevalences of blaOXA-23, blaOXA-24, and blaOXA-58 were 50%, 7.5%, and 5%, respectively. However, the
prevalences of blaTEM-, blaPER-, and blaGES-like genes were 87.5%, 55%, and 27.5%, respectively. SHV, CTX-
M, VEB, KPC, and MBL encoding genes were not detected. The ISAba1 was found upstream to blaOXA-51,
blaOXA-23, and blaADC in 85%, 80%, and 50%, respectively. Of note, 45% (18/40) of the isolates co-produced
extended-spectrum b-lactamases (PER and GES) and carbapenemases (OXA-23 and OXA-58).
Conclusions: The blaADC-, blaTEM-, blaPER-, blaOXA-23-, and blaGES-like genes were found to be the most
prevalent types of b-lactamase-encoding gene in A. baumannii collected from Egypt. A high level of
carbapenem resistance is mediated by blaOXA-23, blaOXA-24, and blaOXA-58 (minimum inhibitory
concentration (MIC) 32 to >256 mg/ml), and a low level of carbapenem resistance is mediated by
blaGES (MIC 4–16 mg/ml) and by up-regulation of ISAba1–OXA-51 (MIC 1–4 mg/ml). Class B MBL was not
identiﬁed to play a role in carbapenem resistance in A. baumannii isolates from Egypt.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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The genus Acinetobacter comprises Gram-negative, aerobic,
glucose-non-fermenting, non-fastidious, non-motile, catalase-
positive, and oxidase-negative bacteria. Acinetobacter baumannii is
an opportunistic pathogen that is an important source of nosocomial
infections, including pneumonia, urinary tract infections, and
wound infections, with high mortality.1 In addition, it is often* Corresponding author. Tel.: +966 553 227 824; fax: +966 1 467 6295.
E-mail addresses: malagamy@ksu.edu.sa, elagamy71@yahoo.com
(M.H. Al-Agamy).
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1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Soresistant to a wide variety of antimicrobial agents, including b-
lactam antibiotics, fosfomycin, and trimethoprim. Therefore, infec-
tions caused by multidrug-resistant A. baumannii are currently
among the most difﬁcult to treat.1,2 A variety of molecular
mechanisms conferring resistance to b-lactams have been reported
in A. baumannii, such as the production of b-lactamases enzymes,
alterations in the outer membrane protein, the production of
penicillin-binding proteins, and increased activity of efﬂux pumps.1
However, the most prevalent mechanism of extended-spectrum
cephalosporin and carbapenem resistance in A. baumannii is
enzymatic degradation by b-lactamases.1–3 The Ambler class A, B,
C, and D b-lactamases confer various resistance phenotypes, such as
extended-spectrum b-lactamases (ESBLs), metallo-b-lactamasesciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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and Acinetobacter-derived cephalosporinases (ADCs).1,2,4–7 Ac-
quired resistance to carbapenem is mediated most often by the
CHDLs (OXA-23, OXA-24/40, OXA-58, and OXA-143) and less
frequently by MBLs (VIM, IMP, SPM, GIM, and NDM), which are
responsible for high levels of carbapenem resistance.5,7–9 Recently,
the Ambler class A carbapenemase GES has been described in A.
baumannii, which is responsible for a low level of carbapenem
resistance.2,3,10–13
The resistance of A. baumannii to extended-spectrum cepha-
losporins is usually related to the over-expression of the resident
Ambler class C blaADC gene,
6,14,15 or infrequently to the acquisition
of ESBL (TEM, SHV, CTX-M, VEB, PER, GES, and KPC) encoding
genes.1–4,10–13,16,17 The PER-, VEB-, and GES-like types are the most
common Ambler class A b-lactamases in A. baumannii.2–4,10–13,18
There is little information on the frequency of occurrence,
prevalence, and distribution of the Ambler class b-lactamases in
Egypt. Therefore, this study was undertaken to determine the
prevalences of the class A, B, C, and D b-lactamases that confer
various b-lactamase resistance phenotypes and to determine the
prevalences of ISAba1 and class 1 integron among A. baumannii
isolates collected from two Egyptian hospitals.
2. Materials and methods
2.1. Bacterial isolates
A total of 40 non-consecutive, unique, imipenem-insusceptible A.
baumannii clinical isolates were collected from Kasr El Aini Hospital,
Cairo and Dar Al Fouad Hospital, Sixth of October City, Egypt over a
period of 3 months from January to March 2012. The isolates were
identiﬁed using the API 20 NE system (bioMe´rieux, Marcy l’Etoile,
France) and conﬁrmed using PCR to detect the intrinsic blaOXA-51.
19
2.2. Determination of the minimum inhibitory concentration (MIC)
The MICs of amikacin, amoxicillin–clavulanate, aztreonam,
cefepime, cefotaxime, ceftazidime, ciproﬂoxacin, imipenem, gen-
tamicin, and colistin were determined for the 40 imipenem-
insusceptible A. baumannii isolates using the British Society for
Antimicrobial Chemotherapy (BSAC) agar dilution method, with
BSAC/European Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoints.20 Escherichia coli ATCC 25922 was used as
the reference strain.
2.3. Phenotypic detection of ESBLs and MBLs
ESBL screening was performed using the disk diffusion method,
in accordance with the Clinical and Laboratory Standards Institute
(CLSI) recommended guidelines.21 ESBL production was conﬁrmedTable 1
Minimum inhibitory concentration (MIC) distributions of antimicrobial agents for 40 i
Antibiotic Resistance pattern, n (%) Distribution
R I S 0.25 
Amoxicillin–clavulanate 40 (100) 0 0 0 
Cefotaxime 40 (100) 0 0 0 
Ceftazidime 40 (100) 0 0 0 
Cefepime 40 (100) 0 0 0 
Aztreonam 40 (100) 0 0 0 
Imipenem 28 (70) 7 (17.5) 5 (12.5) 0 
Amikacin 18 (45) 9 (22.5) 13 (32.5) 0 
Ciproﬂoxacin 34 (85) 0 6 (15) 1 
Colistin 2 (5) 0 38 (95) 19 
R, resistant; I, intermediate; S, susceptible.with Etest ESBL strips (AB Biodisk, Solna, Sweden). Imipenem/
imipenem + ethylenediaminetetraacetic acid (EDTA) E-test MBL
strips (AB Biodisk, Solna, Sweden) were used in accordance with
the manufacturer’s directions to investigate MBL production. A
ratio of the MICs of imipenem to imipenem + EDTA of 8 or the
presence of a phantom zone was taken as a positive result.
2.4. Molecular characterization of antimicrobial resistance
determinants
A series of PCR reactions were performed to detect the
different Ambler class bla genes and mobile genetic elements.
Primers were designed to amplify the following bla gene groups:
class A, blaTEM, blaSHV, blaCTX-M, blaVEB, blaPER, blaKPC, and blaGES;
class B, blaIMP, blaVIM, blaGIM, blaSPM, blaSIM, and blaNDM; class C,
blaADC; and class D, blaOXA-23-like, blaOXA-24-like, blaOXA-51-like,
and blaOXA-58-like.
14,22–24 Integrase genes (int1) and IS elements
(ISAba1) were ampliﬁed by PCR using previously described
methods.25,26 PCR mapping experiments using combinations of
the ISAba1 primers and the OXA-51-like, OXA-23-like, OXA-24-
like, OXA-58-like, and ADC-like reverse primers were carried
out. All PCR assays were performed using Red Load Taq Master
(Jena Bioscience, Jena, Germany) in a Techne thermocycler
(Techne, UK). Positive and negative controls were included in all
PCR assays.
3. Results
3.1. Antimicrobial resistance pattern
The resistance patterns of the 40 A. baumannii isolates and the
MIC distributions of the tested antimicrobial agents are shown in
Table 1. A. baumannii isolates were all resistant to amoxicillin–
clavulanate, aztreonam, cefepime, ceftazidime, and cefotaxime.
The resistance rates to ciproﬂoxacin, imipenem, and amikacin
were 85% (34/40), 70% (28/40), and 45% (18/40), respectively.
Colistin showed the highest activity against A. baumannii isolates;
the resistance rate was 5% (2/40).
3.2. MICs of tested antibiotics against A. baumannii isolates
The MICs and MIC distributions of amoxicillin–clavulanate,
cefotaxime, ceftazidime, cefepime, aztreonam, imipenem, amika-
cin, ciproﬂoxacin, and colistin are shown in Tables 1 and 2.
3.3. Prevalence of ESBLs and MBLs
Etest strips for ESBLs were applied to the 40 isolates, with 30
(75%) giving a positive result. The imipenem/imipenem + EDTA
Etest gave negative MBL results for all isolates.solates of Acinetobacter baumannii
 of MIC (mg/ml)
0.5 1 2 4 8 16 32 64 128 256
0 0 0 0 0 0 0 0 0 40
0 0 0 0 0 0 0 0 0 40
0 0 0 0 0 0 0 1 1 38
0 0 0 0 0 0 0 0 3 37
0 0 0 0 0 0 7 7 4 22
0 2 3 4 3 4 1 3 8 12
0 1 2 3 7 9 4 3 6 5
2 3 2 1 4 4 2 7 8 6
9 8 2 1 1 0 0 0 0 0
Table 2
Clinical data, minimum inhibitory concentrations (MIC), and results of PCR for 40 Acinetobacter baumannii isolates
No. Isolate Clinical data MIC (mg/l)a PCRb,c
Specimen Hospital Date of
collection
Gender AMC CT TZ FP AT IP AK CI COL TEM PER GES IS/Aba1
-ADC
ISAba1
-OXA-51
OXA-23 ISAba1
-OXA-23
OXA-24 OXA-58
1 AB1 Wound
swab
Dar Al Fouad 3/1/2012 Male 256 256 256 256 256 >256 16 64 0.25 + +  + + + +   TEM + PER + ADC +
OXA-51 + OXA-23 +
ISAba1 + int1
2 AB3 Blood Dar Al Fouad 6/1/2012 Female 256 256 256 256 256 256 8 128 0.25 + +  + + + +  
3 AB5 Wound
swab
Kasr El Aini 9/1/2012 Male 256 256 256 256 >256 128 16 64 0.25 + +  + + + +  
4 AB6 Drain Dar Al Fouad 10/1/2012 Male 256 256 256 256 256 128 16 32 0.5 + +  + + + +  
5 AB9 ETT Kasr El Aini 15/1/2012 Male 256 256 256 256 256 >256 16 >256 4 + +  + + + +  
6 AB13 Wound
swab
Dar Al Fouad 27/1/2012 Male 256 256 256 256 256 >256 16 16 0.25 + +  + + + +  
7 AB18 ETT Kasr El Aini 8/2/2012 Male 256 256 256 256 256 128 4 128 0.25 + +  + + + +  
8 AB19 CVP Dar Al Fouad 9/2/2012 Female 256 256 256 256 256 64 8 64 0.25 + +  + + + +  
9 AB20 Sputum Kasr El Aini 14/2/2012 Female 256 256 256 256 256 64 32 256 0.25 + +  + + + +  
10 AB23 Blood Dar Al Fouad 23/2/2012 Female 256 256 256 256 256 128 16 32 0.5 + +  + + + +  
11 AB24 Sputum Kasr El Aini 24/2/2012 Male 256 256 256 256 256 32 32 >256 1 + +  + + + +  
12 AB26 ETT Kasr El Aini 27/2/2012 Male 256 256 256 256 256 256 64 128 0.25 + +  + + + +  
13 AB28 ETT Kasr El Aini 2/3/2012 Male 256 256 256 256 256 64 16 128 0.5 + +  + + + +  
14 AB30 Sputum Kasr El Aini 6/3/2012 Male 256 256 256 256 256 128 8 64 0.5 + +  + + + +  
15 AB33 Sputum Kasr El Aini 10/3/2012 Male 256 256 256 256 128 128 32 128 1 + +  + + + +  
16 AB34 Urine Kasr El Aini 13/3/2012 Female 256 256 256 256 256 >256 64 >256 1 + +  + + + +  
17 AB22 Urine Kasr El Aini 18/2/2012 Female 256 256 256 256 256 >256 128 128 0.5 +    + +    TEM + ADC + OXA-51 +
OXA-23 + ISAba1 + int1
18 AB40 Sputum Dar Al Fouad 25/3/2012 Male 256 256 256 256 256 256 >256 16 8 +    + +   
19 AB14 Blood Kasr El Aini 31/1/2012 Female 256 256 256 256 128 256 >256 256 1 +    + +   
20 AB7 Pus Kasr El Aini 11/1/2012 Male 256 256 256 256 >256 >256 >256 256 0.25 +  + + + +   + TEM + GES + ADC +
OXA-51 + OXA-23 +
OXA-58 ISAba1 + int1
21 AB4 Pus Kasr El Aini 7/1/2012 Male 256 256 256 256 32 128 128 64 0.25 +   + +  +  TEM + ADC + OXA-51 +
OXA-24 + ISAba1 + int1
22 AB8 Sputum Kasr El Aini 13/1/2012 Male 256 256 256 256 256 128 256 128 0.25 +   + +  + 
23 AB37 Unknown Kasr El Aini 17/3/2012 Female 256 256 256 256 256 256 128 64 1 +   + +  + 
24 AB38 Unknown Kasr El Aini 19/3/2012 Male 256 256 256 256 128 >256 8 0.5 1 + +   +   + TEM + PER + ADC +
OXA-51 + OXA-58 +
ISAba1 + int1
25 AB2 Pus Kasr El Aini 5/1/2012 Female 256 256 256 128 64 8 16 1 2 +  +  +   ‘‘ TEM + GES + ADC +
OXA-51 + ISAba1
26 AB10 Unknown Dar Al Fouad 17/1/2012 Female 256 256 256 256 64 16 128 2 0.25 +  +  +   
27 AB15 Blood Kasr El Aini 2/2/2012 Male 256 256 256 256 64 16 16 0.25 0.5 +  +  +   
28 AB16 Urine Kasr El Aini 5/2/2012 Female 256 256 256 256 64 4 >256 8 0.25 +  +  +   
29 AB31 Blood Kasr El Aini 8/3/2012 Male 256 256 256 256 128 4 128 4 1 +  +  +   
30 AB32 Pus Kasr El Aini 8/3/2012 Male 256 256 256 256 64 16 8 8 2 +  +  +   
31 AB12 Pus Kasr El Aini 23/1/2012 Male 256 256 256 256 256 8 2 8 0.25 +  +  +   
32 AB25 Blood Kasr El Aini 26/2/2012 Male 256 256 256 256 64 8 128 1 0.5 +  +  +   
33 AB35 Tissue Kasr El Aini 16/3/2012 Male 256 256 256 256 256 16 1 128 1 +  +  +   
34 AB21 CVP Kasr El Aini 17/2/2013 Female 256 256 256 256 64 4 32 16 0.5 +  +  +   
35 AB11 Pus Kasr El Aini 20/1/2012 Male 256 256 256 256 32 2 4 16 0.25  +       ADC + PER +
OXA-51 + ISAba1
36 AB17 Urine Dar Al Fouad 6/2/2012 Male 256 256 64 128 32 4 8 0.5 0.25  +      
37 AB27 Blood Kasr El Aini 1/3/2012 Male 256 256 256 256 32 1 8 64 0.25  +      
38 AB29 Blood Kasr El Aini 5/3/2012 Female 256 256 256 256 32 2 64 8 0.5  +      
39 AB39 Sputum Kasr El Aini 22/3/2012 Female 256 256 256 128 32 2 2 1 0.25  +      
40 AB36 Blood Dar Al Fouad 16/3/2012 Male 256 256 128 256 32 1 4 2 0.25 +        TEM + ADC +
OXA-51 + ISAba1
ETT, Endotracheal tube; CVP, Central venous catheter.
a AMC, amoxicillin–clavulanate; CT, cefotaxime; TZ, ceftazidime; FP, cefepime; AT, aztreonam; IP, imipenem; AK, amikacin; CI, ciproﬂoxacin; COL, colistin.
b All isolates were negative to SHV, CTX-M, VEB, VIM, IMP, SIM, SPM, GIM, and NDM.
c ADC, int1, OXA-51, ISAba1 were universal.
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The prevalences of four Ambler class b-lactamase-encoding
genes among the 40 A. baumannii isolates are shown in Table 2. The
intrinsic b-lactamase gene, blaOXA-51-like, was ampliﬁed from all
40 A. baumannii isolates. The blaOXA-23 gene was ampliﬁed from 20
isolates (50%). The blaOXA-24/40- and blaOXA-58-like genes were
detected in three isolates (7.5%) and two isolates (5%), respectively.
Class B MBL genes were not detected in the 40 A. baumannii
isolates.
The most prevalent Ambler class A b-lactamase-encoding gene
was blaTEM, which was identiﬁed in 35 (87.5%) isolates; the next
most prevalent gene was blaPER, which was identiﬁed in 22 (55%) of
the isolates. Ambler class A carbapenemase-encoding gene blaGES
was detected in 11 (27.5%) of the 40 A. baumannii isolates.
However, blaSHV, blaCTX-M, blaVEB, and blaKPC encoding genes were
not detected. The prevalence of blaADC, an Ambler class C
cephalosporinase, was 100% in the 40 A. baumannii isolates.
3.5. Upstream regulation of ISAba1
All isolates were found to harbor class 1 integron and ISAba1.
The ISAba1 element was found upstream to the corresponding
genes blaOXA-51, blaOXA-23, and blaADC in 85% (34/40), 80% (16/20),
and 50% (20/40), respectively. However, the ISAba1 element was
not found upstream of either blaOXA-24/40 or blaOXA-58 (Table 2).
4. Discussion
Antimicrobial resistance in A. baumannii has become a
worldwide problem. The emergence of clinical A. baumannii
isolates with diverse antibiotic resistance phenotypes causes
difﬁculties in treating infections caused by this pathogen.3 In the
present study, A. baumannii isolates were 100% resistant to
amoxicillin–clavulanate, third- and fourth-generation cephalos-
porins, and monobactams; however 85% of the isolates were also
found to be resistant to ciproﬂoxacin. Amikacin was found to be an
effective drug in the treatment of A. baumannii isolates; 45% of the
isolates were resistant. The present study is consistent to some
extent with previous studies conducted on A. baumannii collected
from Egypt.8,27,28 In the study of Mohamed and Raafat,8 100% of A.
baumannii isolates (n = 23) were found to be resistant to the third-
and fourth-generation cephalosporins. Furthermore, high resis-
tance rates to amikacin, tobramycin, and ciproﬂoxacin were found:
100%, 82.6%, and 69.6%, respectively. Ahmed et al.27 reported that
A. baumannii isolates (n = 52) were 100% resistant to amoxicillin–
clavulanate, ceftazidime, ciproﬂoxacin, nalidixic acid, and chlor-
amphenicol; however, the resistance rates to amikacin, cefepime,
and cefradine were 76.9%, 80.8%, and 96.2%, respectively. Nasr and
Attalah28 found that all isolates (n = 20) were 100% resistant to
ampicillin–sulbactam, ceftazidime, ceftriaxone, ciproﬂoxacin, and
piperacillin–tazobactam. High resistance rates were also observed
to amikacin (90%), gentamicin (85%), and doxycycline (75%).
Carbapenems have become the drugs of choice for the
treatment of serious nosocomial infections caused by Acineto-
bacter; however, carbapenem-resistant strains of A. baumannii
have been reported worldwide. In the present study, the majority
of the isolates (70%) were resistant to imipenem (MIC >8 mg/ml).
Resistance to carbapenems in clinical A. baumannii isolates has
been notable recently in Egypt. Few studies have determined the
resistance rates for carbapenem in A. baumannii isolates from
Egypt. High resistance rates to carbapenems have been observed in
Egypt, ranging from 75% to 100% for imipenem and from 61% to
77% for meropenem.8,27–30 The resistance to imipenem reﬂects a
problem that might be described as countrywide. In addition, in
the present study, 50% of the isolates displayed unusually highlevels of resistance to imipenem, with MIC values 128 mg/ml. In
the Middle East and North Africa, the occurrence of imipenem-
resistant A. baumannii is recognized with alarm. The resistance rate
of A. baumannii to imipenem was found to be 95% in Turkey, 65% in
Saudi Arabia, 47.9% in Algeria, 45% in Tunisia, and 19.14% in
Kuwait.12,13,31–33 The emergence of A. baumannii strains with
increased carbapenem resistance in this area of the world may be
due to the extensive misuse of carbapenems.
Colistin and tigecycline are the last options for the treatment of
carbapenem-resistant A. baumannii. Lately, A. baumannii isolates
have frequently been found to be resistant to most antimicrobial
agents, and evidence of pan-drug resistance among these isolates
has been reported. A. baumannii isolates resistant to carbapenems,
colistin, and tigecycline have been identiﬁed, making the
treatment of these isolates particularly difﬁcult. The rate of
colistin resistance is relatively low, likely because of its infrequent
use. In the present study, colistin retained its activity against most
of the tested isolates, with a percentage of susceptibility of 95%.
That is consistent with previous studies in Egypt, in which colistin
was found to be active against 82.6%8 and 100%30 of the tested
isolates. In addition, in other studies, it was found that 100% of A.
baumannii was sensitive to colistin in Algeria, 92.5% in Kuwait, and
70.9% in Saudi Arabia.12,31,33
The most prevalent mechanism of carbapenem resistance in A.
baumannii is the enzymatic degradation by carbapenem-
hydrolyzing b-lactamases. The most widespread carbapenemases
in A. baumannii are CHDLs and, to a lesser extent, MBL and class A
carbapenemases.1,3,5,12,13,34 MBL, mostly VIM and IMP, has been
reported sporadically in some parts of the world.1 MBL NDM-1 and
NDM-2 were ﬁrst described in A. baumannii from Egypt,7,35 and
then spread in the Middle East.36MBL VIM, SPM-1, and GIM-1 were
detected previously in A. baumannii isolates from Egypt.8,30
Nevertheless, in the present study, none of the A. baumannii
isolates harbored blaIMP, blaVIM, blaSPM, blaSIM, blaGIM, or blaNDM
MBL-encoding genes.
CHDLs can be divided into four main subgroups: the intrinsic
blaOXA-51-like and the acquired carbapenemase genes blaOXA-23-,
blaOXA-24/40-, and blaOXA-58-like.
1 Numerous studies have recently
reported that blaOXA-23 is the most frequent type of carbapenemase
identiﬁed among carbapenem-resistant A. baumannii.1,12,13,29,30,37
In this study, the most prevalent CHDL-encoding gene in A.
baumannii was blaOXA-23, with a prevalence rate of 50% (n = 20),
which is in agreement with previous studies.12,13,29 However,
Fouad et al.30 detected blaOXA-23 in their entire collection of A.
baumannii isolates. blaOXA-24/40 has mostly been found in the Asian
and Iberian peninsulas, but has also been detected in other
areas.1,12,13,38,39 The OXA-58 gene has been reported in isolates of
A. baumannii scattered throughout different parts of the world,
including Algeria, Argentina, Italy, Kuwait, Turkey, the UK, and the
USA.1,37,40–43 In this study, the prevalence of the OXA-58-encoding
gene in the clinical isolates of A. baumannii was found to be 5% (2/
40). In Egypt and Algeria, 9.1% and 14.7%, respectively, of
carbapenem-resistant A. baumannii isolates were found to produce
OXA-58.29,37 Additionally, in Italy and Turkey, carbapenem
resistance of A. baumannii has consistently been related to the
production of blaOXA-58.
41,42 Only a few studies on carbapenemases
in A. baumannii in Egypt are available.7,8,29,35 In the present study,
all three acquired class D carbapenemases OXA-23-, OXA-24/40-,
and OXA-58-encoding genes were identiﬁed among the tested
strains correlating with resistance to carbapenems, with pre-
valences of 50%, 7.5%, and 5%, respectively. In a recent study
conducted in Egypt by Al-Hassan et al., the prevalences of OXA-23,
OXA-40, and OXA-58 were 55.88%, 2.9%, and 14.7%, respectively.29
The prevalence of OXA-23 in the present study is very similar to
that found in the study of Al-Hassan et al.; however, the prevalence
of OXA-24 in the present study is higher than that found in the
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of blaOXA-23, blaOXA-24, and blaOXA-58 were lower. It is worth noting
that the presence of the blaOXA-23 carbapenemase-encoding gene
along with the coexistence of blaOXA-58 was detected in one strain
in the present study. This ﬁnding is in agreement with other
studies.29,37,38
The blaOXA-51-like gene is unique in that it occurs naturally in A.
baumannii. Therefore, it is chromosomally located and is widely
prevalent. Many studies have indicated that the identiﬁcation of
the blaOXA-51-like gene is a reliable and rapid method to
presumptively identify A. baumannii. In addition, the identiﬁcation
of this gene reveals that the rate of antibiotic resistance to various
antibiotics is high in A. baumannii isolates.19 Insertion sequences
(IS) may contribute to the over-production and dissemination of b-
lactamase.25,43 The over-expression of CHDL-encoding genes,
driven mostly by promoters provided by their upstream ISs, is
one of the means by which A. baumannii acquires a high level of
carbapenem resistance. ISAba1 and ISAba825 upstream to the
blaOXA-51-like gene are associated with the over-expression of the
blaOXA-51-like and other CHDL-encoding genes along with carba-
penem resistance in A. baumannii.12,13,43 However, some isolates
harboring the blaOXA-51-like gene with an upstream ISAba1 are still
susceptible to carbapenems (Pagano et al.44). The present study
revealed that all A. baumannii isolates had blaOXA-51 and ISAba1. The
ISAba1 element was found upstream to the corresponding genes
blaOXA-51, blaOXA-23, and blaADC in 85% (34/40), 80% (16/20), and 50%
(20/40), respectively. However, the ISAba1 element was not found
upstream of either blaOXA-24/40 or blaOXA-58. The ISAba1 element
was not found upstream of blaOXA-51 in six (15%) isolates with
imipenem MICs ranging from 1 to 4 mg/ml. The up-regulation of
ISAba1 to blaOXA-51 was found in 34 isolates. Twenty-ﬁve out of 34
isolates were concomitant with other CHDLs that had markedly
high MICs for imipenem (32 mg/ml): blaOXA-23 (n = 19), blaOXA-24
(n = 3), blaOXA-58 (n = 1), and one isolate co-produced blaOXA-23 and
blaOXA-58. Nine of 34 isolates were not concomitant with other
CHDLs, with lower MICs for carbapenems (2–8 mg/ml). In the
present study, up-regulation of ISAba1 played an important role in
the over-expression of blaOXA-51, blaOXA-23, and blaADC.
GES variants and KPC are Ambler class A carbapenemases that
have been reported in the last 5 years in A. baumannii;3,12,13,17 our
isolates were tested for their encoding genes. Our results revealed
that A. baumannii were devoid of KPC, but GES was detected in
27.5% (11/40) of the isolates. In the present study, the prevalence of
GES is in agreement with the ﬁndings of previous Turkish and
Saudi studies,12,13 with prevalences of 23.8% and 34.5%, respec-
tively. Several GES-1 mutants have been detected in A. baumannii,
such as GES-11, GES-12, GES-14, and GES-22.2,3,10,11,13 Unfortu-
nately, in the current study, GES-encoding genes were not
sequenced; however from the MIC data it can be concluded that
they may be GES-1 variants, which possess carbapenemase
activity. Several studies detecting GES in A. baumannii have been
published recently. GES-11 has been reported from Turkey, Egypt,
Kuwait, Gaza, and France.3,10,11,13 GES-12 has been detected in
Egypt, Belgium, and France, and in addition, GES-14 has been
detected in Turkey and Kuwait.3,11 GES-22 has been detected in
Turkey.13 GES was detected concomitant with OXA-51 (n = 10) or
in combination with OXA-23 plus OXA-58 (n = 1). Ten GES-positive
isolates, which had GES plus OXA-51, had imipenem MICs ranging
from 4 to 16 mg/ml. This result indicates that the GES-1 mutant is
responsible for a high level of carbapenem resistance and/or up-
regulation of ISAba1 to OXA-51.
Several Ambler class A ESBLs have been identiﬁed in A.
baumannii, such as CTX-15, PER-1, PER-2, PER-7, and VEB-
1.4,16,18 PER and, to a lesser extent, VEB are the most common
Ambler class A ESBLs in A. baumannii.4,12,18,45–48 Our isolates were
tested for PER, VEB, TEM, SHV, and CTX-M genes. Our resultsrevealed that A. baumannii were devoid of VEB, SHV, and CTX-M,
but TEM and PER were detected in 87.5% and 49.1% of A. baumannii
isolates, respectively. PER has been documented in Acinetobacter
isolates from France, Belgium, India, Iran, South Korea, Saudi
Arabia, and Argentina.4,18,45–48 PER-1, PER-2, and PER-7 have been
detected previously in A. baumannii.4,45–48 In Iran and Korea, 51%
and 54%, respectively, of nosocomial isolates of Acinetobacter spp
were found to produce PER-1,18,46 and our results agree with those
studies.
The most common mechanism of resistance of A. baumannii to
b-lactam antibiotics is attributed to the presence of a chromo-
somal cephalosporinase-encoding gene.14,15 Most AmpC-type b-
lactamases naturally produced by Gram-negative bacteria hydro-
lyze amino- and ureidopenicillins, cephamycins, and, at a low level,
oxyiminocephalosporins, such as ceftazidime, cefotaxime, ceftri-
axone, and aztreonam. Several allelic variants of the A. baumannii
AmpC enzyme have also been reported.14 Recently, a uniform
designation for this family of cephalosporinases has been
suggested: ADC, with AmpCs of A. baumannii.6,14 The enzyme is
normally expressed at low levels and is not inducible, but over-
expression occurs with the upstream insertion of ISAba1 common
in A. baumannii, which provides an efﬁcient promoter for the
blaAmpC gene. In this study, the entire collection had ADC, 40% of
which harbored the upstream ISAba1. The detection of Int1 is
considered a good indicator for the spread of epidemic Acineto-
bacter isolates and it can be responsible for the integration of
resistance markers either on the chromosome or plasmid.26 In the
present study, the prevalence of Int1 was universal; however in a
recent study from Egypt, the prevalence of Int1 was detected in 85%
of Acinetobacter isolates.30
Current knowledge of A. baumannii is presented in this paper.
This report highlights the emergence of blaOXA-23-like and blaGES-
like genes, especially those conferring carbapenem resistance in A.
baumannii. We can conclude that these isolates were devoid of
class B MBL. PER-1 is the dominant ESBL and ADC is the dominant
extended-spectrum cephalosporinase. ISAba1 plays an important
role in the over-expression of blaOXA-51. To our knowledge, PER-,
GES- and ADC-like have not been reported in A. baumannii from
Egypt. Heterogeneous groups of b-lactamases were identiﬁed in
our isolates.
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